|
1
|
Desgrosellier JS and Cheresh DA: Integrins
in cancer: Biological implications and therapeutic opportunities.
Nat Rev Cancer. 10:9–22. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
2
|
Howe GA and Addison CL: β1 integrin: An
emerging player in the modulation of tumorigenesis and response to
therapy. Cell Adh Migr. 6:71–77. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Calderwood DA, Campbell ID and Critchley
DR: Talins and kindlins: Partners in integrin-mediated adhesion.
Nat Rev Mol Cell Biol. 14:503–517. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Legate KR, Montañez E, Kudlacek O and
Fässler R: ILK, PINCH and parvin: The tIPP of integrin signalling.
Nat Rev Mol Cell Biol. 7:20–31. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ewald AJ and Egeblad M: Cancer:
Sugar-coated cell signalling. Nature. 511:298–299. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Paszek MJ, DuFort CC, Rossier O, Bainer R,
Mouw JK, Godula K, Hudak JE, Lakins JN, Wijekoon AC, Cassereau L,
et al: The cancer glycocalyx mechanically primes integrin-mediated
growth and survival. Nature. 511:319–325. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Reverter M, Rentero C, Garcia-Melero A,
Hoque M, Vilà de Muga S, Alvarez-Guaita A, Conway JR, Wood P,
Cairns R, Lykopoulou L, et al: Cholesterol regulates Syntaxin 6
trafficking at trans-Golgi network endosomal boundaries. Cell Rep.
7:883–897. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Liu H, Radisky DC, Yang D, Xu R, Radisky
ES, Bissell MJ and Bishop JM: MYC suppresses cancer metastasis by
direct transcriptional silencing of αv and β3 integrin subunits.
Nat Cell Biol. 14:567–574. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Madamanchi A, Zijlstra A and Zutter MM:
Flipping the switch: Integrin switching provides metastatic
competence. Sci Signal. 7:pe92014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Parvani JG, Galliher-Beckley AJ, Schiemann
BJ and Schiemann WP: Targeted inactivation of β1 integrin induces
β3 integrin switching, which drives breast cancer metastasis by
TGF-β. Mol Biol Cell. 24:3449–3459. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Truong HH, Xiong J, Ghotra VP, Nirmala E,
Haazen L, Le Dévédec SE, Balcioğlu HE, He S, Snaar-Jagalska BE,
Vreugdenhil E, et al: β1 integrin inhibition elicits a
prometastatic switch through the TGFβ-miR-200-ZEB network in
E-cadherin-positive triple-negative breast cancer. Sci Signal.
7:ra152014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Grzesiak JJ, Smith KC, Burton DW, Deftos
LJ and Bouvet M: Integrin-mediated laminin-1 adhesion upregulates
CXCR4 and IL-8 expression in pancreatic cancer cells. Surgery.
141:804–814. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Aoudjit F and Vuori K: Integrin signaling
inhibits paclitaxel-induced apoptosis in breast cancer cells.
Oncogene. 20:4995–5004. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Jin JK, Tien PC, Cheng CJ, Song JH, Huang
C, Lin SH and Gallick GE: Talin1 phosphorylation activates β1
integrins: A novel mechanism to promote prostate cancer bone
metastasis. Oncogene. 34:1811–1821. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lee YC, Jin JK, Cheng CJ, Huang CF, Song
JH, Huang M, Brown WS, Zhang S, Yu-Lee LY, Yeh ET, et al: Targeting
constitutively activated β1 integrins inhibits prostate cancer
metastasis. Mol Cancer Res. 11:405–417. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Bartolome RA, Barderas R, Torres S,
Fernandez-Aceñero MJ, Mendes M, García-Foncillas J, Lopez-Lucendo M
and Casal JI: Cadherin-17 interacts with α2β1 integrin to regulate
cell proliferation and adhesion in colorectal cancer cells causing
liver metastasis. Oncogene. 33:1658–1669. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Benaud CM and Dickson RB: Regulation of
the expression of c-Myc by beta1 integrins in epithelial cells.
Oncogene. 20:759–768. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhu J, He J, Liu Y, Simeone DM and Lubman
DM: Identification of glycoprotein markers for pancreatic cancer
CD24+CD44+ stem-like cells using nano-LC-MS/MS and tissue
microarray. J Proteome Res. 11:2272–2281. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Muller PA, Caswell PT, Doyle B, Iwanicki
MP, Tan EH, Karim S, Lukashchuk N, Gillespie DA, Ludwig RL,
Gosselin P, et al: Mutant p53 drives invasion by promoting integrin
recycling. Cell. 139:1327–1341. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Selivanova G and Ivaska J: Integrins and
mutant p53 on the road to metastasis. Cell. 139:1220–1222. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ashour AA, Gurbuz N, Alpay SN, Abdel-Aziz
AA, Mansour AM, Huo L and Ozpolat B: Elongation factor-2 kinase
regulates TG2/β1 integrin/Src/uPAR pathway and
epithelial-mesenchymal transition mediating pancreatic cancer cells
invasion. J Cell Mol Med. 18:2235–2251. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Huang WS, Chin CC, Chen CN, Kuo YH, Chen
TC, Yu HR, Tung SY, Shen CH, Hsieh YY, Guo SE, et al: Stromal
cell-derived factor-1/CXC receptor 4 and β1 integrin interaction
regulates urokinase-type plasminogen activator expression in human
colorectal cancer cells. J Cell Physiol. 227:1114–1122. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Jahangiri A, Aghi MK and Carbonell WS: β1
integrin: Critical path to antiangiogenic therapy resistance and
beyond. Cancer Res. 74:3–7. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Pontes-Junior J, Reis ST, Bernardes FS,
Oliveira LC, Barros ÉA, Dall'Oglio MF, Timosczuk LM, Ribeiro-Filho
LA, Srougi M and Leite KR: Correlation between β1 integrin
expression and prognosis in clinically localized prostate cancer.
Int Braz J Urol. 39:335–343. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Danen EH, Ten Berge PJ, Van Muijen GN,
Van't Hof-Grootenboer AE, Bröcker EB and Ruiter DJ: Emergence of
alpha 5 beta 1 fibronectin- and alpha v beta 3 vitronectin-receptor
expression in melanocytic tumour progression. Histopathology.
24:249–256. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Matsuoka T, Yashiro M, Nishimura S, Inoue
T, Fujihara T, Sawada T, Kato Y, Seki S and Hirakawa-Ys Chung K:
Increased expression of alpha2beta1-integrin in the peritoneal
dissemination of human gastric carcinoma. Int J Mol Med. 5:21–25.
2000.PubMed/NCBI
|
|
27
|
Hong YM, Gan WG and Xu ZH: Significance of
the expression of integrin β1, VEGF and MVD in hypopharyngeal
squamous cell carcinoma. Genet Mol Res. 13:6455–6465. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
dos Santos PB, Zanetti JS, Ribeiro-Silva A
and Beltrão EI: Beta 1 integrin predicts survival in breast cancer:
A clinicopathological and immunohistochemical study. Diagn Pathol.
7:1042012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Gonzalez MA, Pinder SE, Wencyk PM, Bell
JA, Elston CW, Nicholson RI, Robertson JF, Blamey RW and Ellis IO:
An immunohistochemical examination of the expression of E-cadherin,
alpha- and beta/gamma-catenins, and alpha2- and beta1-integrins in
invasive breast cancer. J Pathol. 187:523–529. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Restucci B, De Vico G and Maiolino P:
Expression of beta 1 integrin in normal, dysplastic and neoplastic
canine mammary gland. J Comp Pathol. 113:165–173. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Desgrosellier JS, Barnes LA, Shields DJ,
Huang M, Lau SK, Prévost N, Tarin D, Shattil SJ and Cheresh DA: An
integrin alpha(v)beta(3)-c-Src oncogenic unit promotes
anchorage-independence and tumor progression. Nat Med.
15:1163–1169. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
32
|
Galliher AJ and Schiemann WP: Beta3
integrin and Src facilitate transforming growth factor-beta
mediated induction of epithelial-mesenchymal transition in mammary
epithelial cells. Breast Cancer Res. 8:R422006. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Reynolds LE, Wyder L, Lively JC, Taverna
D, Robinson SD, Huang X, Sheppard D, Hynes RO and Hodivala-Dilke
KM: Enhanced pathological angiogenesis in mice lacking beta3
integrin or beta3 and beta5 integrins. Nat Med. 8:27–34. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Seguin L, Kato S, Franovic A, Camargo MF,
Lesperance J, Elliott KC, Yebra M, Mielgo A, Lowy AM, Husain H, et
al: An integrin β3 KRAS-RalB complex drives tumour stemness and
resistance to EGFR inhibition. Nat Cell Biol. 16:457–468. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zheng DQ, Woodard AS, Fornaro M, Tallini G
and Languino LR: Prostatic carcinoma cell migration via
alpha(v)beta3 integrin is modulated by a focal adhesion kinase
pathway. Cancer Res. 59:1655–1664. 1999.PubMed/NCBI
|
|
36
|
Hosotani R, Kawaguchi M, Masui T, Koshiba
T, Ida J, Fujimoto K, Wada M, Doi R and Imamura M: Expression of
integrin alphaVbeta3 in pancreatic carcinoma: Relation to MMP-2
activation and lymph node metastasis. Pancreas. 25:e30–e35. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
McCabe NP, De S, Vasanji A, Brainard J and
Byzova TV: Prostate cancer specific integrin alphavbeta3 modulates
bone metastatic growth and tissue remodeling. Oncogene.
26:6238–6243. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Sloan EK, Pouliot N, Stanley KL, Chia J,
Moseley JM, Hards DK and Anderson RL: Tumor-specific expression of
alphavbeta3 integrin promotes spontaneous metastasis of breast
cancer to bone. Breast Cancer Res. 8:R202006. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Vaillant F, Asselin-Labat ML, Shackleton
M, Forrest NC, Lindeman GJ and Visvader JE: The mammary progenitor
marker CD61/beta3 integrin identifies cancer stem cells in mouse
models of mammary tumorigenesis. Cancer Res. 68:7711–7717. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Robinson SD and Hodivala-Dilke KM: The
role of β3-integrins in tumor angiogenesis: Context is everything.
Curr Opin Cell Biol. 23:630–637. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Shah PP, Fong MY and Kakar SS: PTTG
induces EMT through integrin αVβ3-focal adhesion kinase signaling
in lung cancer cells. Oncogene. 31:3124–3135. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Besse B, Tsao LC, Chao DT, Fang Y, Soria
JC, Almokadem S and Belani CP: Phase Ib safety and pharmacokinetic
study of volociximab, an anti-α5β1 integrin antibody, in
combination with carboplatin and paclitaxel in advanced
non-small-cell lung cancer. Ann Oncol. 24:90–96. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Gramoun A, Shorey S, Bashutski JD, Dixon
SJ, Sims SM, Heersche JN and Manolson MF: Effects of Vitaxin, a
novel therapeutic in trial for metastatic bone tumors, on
osteoclast functions in vitro. J Cell Biochem. 102:341–352. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Khalili P, Arakelian A, Chen G, Plunkett
ML, Beck I, Parry GC, Doñate F, Shaw DE, Mazar AP and Rabbani SA: A
non-RGD-based integrin binding peptide (ATN-161) blocks breast
cancer growth and metastasis in vivo. Mol Cancer Ther. 5:2271–2280.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Mulgrew K, Kinneer K, Yao XT, Ward BK,
Damschroder MM, Walsh B, Mao SY, Gao C, Kiener PA, Coats S, et al:
Direct targeting of alphavbeta3 integrin on tumor cells with a
monoclonal antibody, Abegrin. Mol Cancer Ther. 5:3122–3129. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Reardon DA, Fink KL, Mikkelsen T,
Cloughesy TF, O'Neill A, Plotkin S, Glantz M, Ravin P, Raizer JJ,
Rich KM, et al: Randomized phase II study of cilengitide, an
integrin-targeting arginine-glycine-aspartic acid peptide, in
recurrent glioblastoma multiforme. J Clin Oncol. 26:5610–5617.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Vansteenkiste J, Barlesi F, Waller CF,
Bennouna J, Gridelli C, Goekkurt E, Verhoeven D, Szczesna A, Feurer
M, Milanowski J, et al: Cilengitide combined with cetuximab and
platinum-based chemotherapy as first-line treatment in advanced
non-small-cell lung cancer (NSCLC) patients: Results of an
open-label, randomized, controlled phase II study (CERTO). Ann
Oncol. 26:1734–1740. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Delbaldo C, Raymond E, Vera K,
Hammershaimb L, Kaucic K, Lozahic S, Marty M and Faivre S: Phase I
and pharmacokinetic study of etaracizumab (Abegrin), a humanized
monoclonal antibody against alphavbeta3 integrin receptor, in
patients with advanced solid tumors. Invest new Drugs. 26:35–43.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Gutheil JC, Campbell TN, Pierce PR,
Watkins JD, Huse WD, Bodkin DJ and Cheresh DA: Targeted
antiangiogenic therapy for cancer using Vitaxin: A humanized
monoclonal antibody to the integrin alphavbeta3. Clin Cancer Res.
6:3056–3061. 2000.PubMed/NCBI
|
|
50
|
Bhaskar V, Zhang D, Fox M, Seto P, Wong
MH, Wales PE, Powers D, Chao DT, Dubridge RB and Ramakrishnan V: A
function blocking anti-mouse integrin alpha5beta1 antibody inhibits
angiogenesis and impedes tumor growth in vivo. J Transl Med.
5:612007. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Cianfrocca ME, Kimmel KA, Gallo J, Cardoso
T, Brown MM, Hudes G, Lewis N, Weiner L, Lam GN, Brown SC, et al:
Phase 1 trial of the antiangiogenic peptide ATN-161
(Ac-PHSCN-NH(2)), a beta integrin antagonist, in patients with
solid tumours. Br J Cancer. 94:1621–1626. 2006. View Article : Google Scholar : PubMed/NCBI
|
